PROFILE

EDUCATION

1998.12. ~ 2000.11.  Research Associate Scientist, School of Medicine, Yale University
1988.03. ~ 1991.02.  Ph.D. in Medicine, Graduate School of Jeonbuk National University, Korea
1986.03. ~ 1988.02.  M.Sc. in Medicine, Graduate School of Jeonbuk National University, Korea
1980.03. ~ 1986.02.  M.D., College of Medicine, Jeonbuk National University, Korea

PROFESSIONAL EXPERIENCE

2024.03. ~ present    CEO, Korea Drug Development Fund
2023.03. ~ present    Professor, Department of Integrative Biological Sciences and Industry,
Sejong University
2016.06. ~ 2022.12.  Director, Medical Science Research Center(MRC), 
Ministry of Science and ICT, Korea
2016.09 ~ 2021.01   Director, Institute of Biomedical Sciences & Technology, 
Konkuk University, Korea
2013.08 ~ 2015.07.  Director, Medical and Pharmaceutical Division, Basic Research Headquarters, National Research Foundation of Korea

RESEARCH ACTIVITIES & OTHERS

Biomaterials, 2022Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system(Corresponding author, IF: 14.0)
 Journal for ImmunoTherapy of Cancer, 2022Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches(Corresponding author, IF: 10.9)
 Translational Neurodegeneration, 2021Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: Pathologic roles and therapeutic implications(Corresponding author, IF: 12.6)
 Experimental & Molecular Medicine, 2020Interactions between tumor-derived proteins and Toll-like receptors(Corresponding author, IF: 12.8)
 Nature Communications, 2020Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment(Corresponding author, IF: 16.6)